| abstract |
The present invention relates to anti-IL13 antibodies that specifically bind to glycated and unglycosylated human IL13 but not to mouse IL13 and neutralize the activity of human IL13 in a molar ratio of about 1: 2 (MAb: IL13). In addition, the present invention includes asthma, allergic asthma, non-allergic (endogenous) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergy, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, It relates to the use of said antibody in the treatment of IL-13 mediated diseases such as allergic diseases including uveitis, scleroderma or osteoporosis. |